logging in or signing up EuroPCR2010 antiplatelet Rx aSGuest52346 Download Post to : URL : Related Presentations : Let's Connect Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Copy embed code: Embed: Flash iPad Dynamic Copy Does not support media & animations Automatically changes to Flash or non-Flash embed WordPress Embed Customize Embed URL: Copy Thumbnail: Copy The presentation is successfully added In Your Favorites. Views: 517 Category: Entertainment License: All Rights Reserved Like it (0) Dislike it (0) Added: July 02, 2010 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript Comparing ticagrelor versus prasugrel for the treatment of patients with acute coronary syndromes: evidence from a 32,983-patient adjusted indirect comparison meta-analysis : Comparing ticagrelor versus prasugrel for the treatment of patients with acute coronary syndromes: evidence from a 32,983-patient adjusted indirect comparison meta-analysis Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy Background : Dual antiplatelet therapy with aspirin and clopidogrel is effective and safe in patients with acute coronary syndromes (ACS). Recent data suggest a superior anti-thrombotic efficacy of both prasugrel and ticagrelor in combination to aspirin instead of clopidogrel. However, there is yet no direct comparison of prasugrel vs. ticagrelor. Background Aim : We aimed to perform a systematic review and meta-analysis employing adjusted indirect comparison methods comparing prasugrel vs. ticagrelor plus aspirin in patients with ACS. Aim Methods : We searched PubMed for: randomized clinical trials reporting on the comparison of prasugrel vs. clopidogrel or ticagrelor vs. clopidogrel in patients with ACS reporting on at least 1-month events The primary end-point was the rate of major adverse cardiac events (MACE, ie death, myocardial infarction or stroke). Methods Methods : Secondary end-points included components of MACE, Academic Research Consortium definite stent thrombosis, TIMI major bleeding (not related to CABG), and compliance. Standard and adjusted indirect comparison odds ratios (OR) were computed (with 95% confidence intervals) according to Song et al, BMJ 2003;326:472. Methods Results : From 289 initial citations, 3 trials were finally retrieved, enrolling 32,893 patients. Either prasugrel or ticagrelor appeared superior to clopidogrel for 9-month death (OR=0.83 [0.74-0.93], p<0.001), myocardial infarction (OR=0.79 [0.73-0.86], p<0.001), MACE (OR=0.83 [0.77- 0.89], p<0.001), and stent thrombosis (OR=0.55 [0.45-0.68], p<0.001). No differences in stroke (OR=0.90 [0.73-1.11], p=0.320) were found, despite more bleedings (OR=1.28 [1.09-1.49], and discontinuation (OR=1.08 [1.02-1.15], p=0.01). Results Results : Head-to-head comparison of prasugrel vs. ticagrelor showed no significant differences in the risk of death (OR=1.22 [0.96-1.55], p=0.106), myocardial infarction (OR=0.89 [0.75-1.06], p=0.202), stroke (OR=1.19 [0.77-1.84], p=0.441), MACE (OR=0.99 [0.86-1.13], p=0.862), stent thrombosis (OR=0.71 [0.47-1.09], p=0.115), or major bleeding (OR=1.06 [0.77-1.45], p=0.738). Conversely, treatment discontinuation was more frequent with ticagrelor (OR=0.85 [0.72-1.00], p=0.053). Results Comparison of prasugrel or ticagrelor vs. clopidogrel : Comparison of prasugrel or ticagrelor vs. clopidogrel Funnel plots comparing prasugrel or ticagrelor vs. clopidogrel for the risk of: death, myocardial infarction or stroke (A); death (B); myocardial infarction (C); stroke (D); definite or probable stent thrombosis (E). Comparison of prasugrel or ticagrelor vs. clopidogrel : Comparison of prasugrel or ticagrelor vs. clopidogrel Funnel plots comparing prasugrel or ticagrelor vs. clopidogrel for the risk of: major bleeding (A); major non-CABG bleeding (B); major CABG-bleeding (C); any bleeding (D); minor bleeding (E); discontinuation (F) Indirect comparison of prasugrel vs. ticagrelor : Indirect comparison of prasugrel vs. ticagrelor Funnel plots comparing prasugrel vs. ticagrelor for the risk of key clinical events. Odds ratios (OR) <1.0 favor prasugrel, whereas odds ratios>1.0 favor ticagrelor. Conclusions : New antiplatelet agents such as prasugrel and ticagrelor are both more potent than clopidogrel for patients with ACS. Head-to-head comparison suggests that they are largely similar in efficacy and safety, even if prasugrel appears more tolerated than ticagrelor. Conclusions Thank you for your attentionFor any correspondence: firstname.lastname@example.orgFor these and further slides on these topics feel free to visit the metcardio.org website:http://www.metcardio.org/slides.html : Thank you for your attentionFor any correspondence: email@example.comFor these and further slides on these topics feel free to visit the metcardio.org website:http://www.metcardio.org/slides.html You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.